Cowden Syndrome: A Comprehensive Disease Characteristics Report

Disease: Cowden Syndrome (CS) — a PTEN Hamartoma Tumor Syndrome (PHTS) **Category:** Mendelian (autosomal dominant) **Suggested MONDO ID:** MONDO:0016063 (Cowden disease) / part of the PHTS spectrum **Report scope:** Aggregated disease-level synthesis of primary literature and guideline resources (not derived from an individual EHR cohort held by this investigation)

Summary

Cowden syndrome is a rare, autosomal-dominant, multi-system hamartoma-and-cancer predisposition disorder that constitutes the prototypical member of the **PTEN hamartoma tumor syndrome (PHTS)** spectrum. It is caused chiefly by germline loss-of-function mutations in the **PTEN** tumor-suppressor gene at chromosome **10q23.31**. PTEN is a dual-specificity lipid/protein phosphatase that dephosphorylates PIP3 to PIP2, thereby antagonizing the **PI3K/AKT/mTOR** signaling cascade. When PTEN function is lost, this growth-and-survival pathway is de-repressed, driving the hamartomas, benign overgrowth, macrocephaly, neurodevelopmental features, and markedly elevated multi-organ cancer risks that define the syndrome PMID: 26827793; PMID: 25916396.

The clinical burden is dominated by cancer risk. A large prospective study of PHTS-criteria individuals demonstrated dramatically elevated standardized incidence ratios (SIRs) for breast (SIR 25.4; lifetime ~85%), thyroid (SIR 51.1; ~35%), endometrial (SIR 42.9; ~28%), renal (SIR 30.6; ~34%), colorectal (SIR 10.3; ~9%), and melanoma (SIR 8.5; ~6%) cancers PMID: 22252256. Beyond oncologic risk, patients frequently exhibit near-universal macrocephaly, autism spectrum disorder characteristics in approximately one-quarter of carriers, a distinctive pan-gastrointestinal hamartomatous polyposis, and the pathognomonic cerebellar lesion Lhermitte-Duclos disease.

Cowden syndrome is genetically heterogeneous. A substantial minority of clinically diagnosed, PTEN-mutation-negative patients are explained by alternative mechanisms including germline **KLLN** promoter hypermethylation (epimutation) and germline **SDHB/SDHD** variants, both of

which converge on a shared mitochondrial-dysfunction/elevated-succinate biochemical signature. Management is guideline-based (ERN GENTURIS / NCCN): germline genetic testing, intensive organ-specific cancer surveillance, risk-reducing surgery, and genetic counseling. Molecularly targeted PI3K/mTOR inhibition remains experimental — with encouraging anecdotal hamartoma responses (e.g., rapamycin in Lhermitte-Duclos disease) but a **negative primary endpoint** in the randomized everolimus trial for neurocognitive symptoms.

---

1. Disease Information

Overview. Cowden syndrome is a rare autosomal-dominant disorder characterized by multiple hamartomas (benign disorganized overgrowths) across ectodermal, mesodermal, and endodermal tissues, together with a substantially increased lifetime risk of breast, thyroid, endometrial, renal, and colorectal cancers plus melanoma. It is the flagship condition of the **PTEN hamartoma tumor syndrome (PHTS)** umbrella, which also encompasses Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome, and Lhermitte-Duclos disease (adult-onset).

Key identifiers (suggested): - **OMIM:** 158350 (Cowden syndrome 1, PTEN-related); allelic/related PHTS entries - **Orphanet:** ORPHA:201 (Cowden syndrome) - **MONDO:** MONDO:0016063 - **MeSH:** Hamartoma Syndrome, Multiple (D006223) - **ICD-10:** Q85.8 (Other phakomatoses, not elsewhere classified) - **ICD-11:** LD2D.Y / relevant hamartoneoplastic syndrome code

Synonyms / alternative names: Cowden disease; multiple hamartoma syndrome; PTEN hamartoma tumor syndrome (as the encompassing molecular class); Cowden-like syndrome (for clinically compatible, PTEN-negative cases).

Information source type: This report is derived from **aggregated, disease-level resources** — primary literature (prospective cohorts, case series, guidelines) and curated ontologies — rather than from an individual-patient EHR dataset.

---

2. Etiology

Primary causal factor — genetic. The predominant cause is a germline loss-of-function mutation in **PTEN** (10q23.31), inherited in an autosomal-dominant fashion. "Inherited loss of function mutations in the PTEN gene were originally identified in sufferers of Cowden disease"

PMID: 26827793. PTEN acts as a tumor suppressor and a brake on the PI3K/AKT/mTOR pathway; its germline haploinsufficiency, with somatic second-hit inactivation in lesions, initiates hamartoma and tumor formation.

Genetic risk factors. - **Causal variant:** germline PTEN pathogenic/likely-pathogenic variants (nonsense, frameshift, missense, splice-site, and promoter mutations; large deletions including 10q23 microdeletions). - **Genotype–phenotype correlations:** promoter mutations are associated with breast cancer, and nonsense mutations with colorectal cancer, in PTEN carriers PMID: 22252256. Catalytically inactive but stable PTEN mutants correlate with the most severe phenotypes, whereas partial-function mutants associate with milder, autism-predominant phenotypes PMID: 25916396. - **Alternative loci (PTEN-negative cases):** germline **KLLN** epimutation and **SDHB/SDHD** variants (see Section 4). - **Candidate modifier:** a **SMAD7** missense variant co-occurring with a PTEN frameshift was proposed as a modifier in a family with hamartomatous polyposis and early-onset esophageal cancer PMID: 25554686.

Environmental / demographic risk factors. No specific environmental trigger causes Cowden syndrome; it is a monogenic disorder. Age and sex modulate expression: female carriers face high breast/endometrial cancer risk; cancer risks are age-dependent and cumulative. Family history is the principal actionable risk factor (cascade testing).

Protective factors. No validated genetic or environmental protective alleles are established for Cowden syndrome. Practically, "protection" is achieved through surveillance and risk-reducing surgery rather than intrinsic modifiers.

Gene–environment interactions. Evidence is limited. The mouse-model observation that simultaneous disruption of PTEN and TGF-β/SMAD signaling promotes esophageal cancer suggests pathway-level genetic interactions rather than classical gene–environment effects PMID: 25554686.

---

3. Phenotypes

Cowden syndrome is a pleomorphic multi-system disorder. Major phenotype domains and characteristics:

Phenotype	Type	Frequency	Onset / course	Suggested HPO
Macrocephaly	Physical/ clinical sign	~100% in pediatric PHTS cohorts	Congenital/ early, stable	HP:0000256
Autism spectrum disorder characteristics	Behavioral	~25% (95% CI 16–33%)	Childhood	HP:0000717
Developmental delay	Behavioral/ neurodev	~58% early childhood	Childhood	HP:0001263
Trichilemmomas / mucocutaneous lesions	Physical manifestation	Very common, characteristic	Adult-onset	HP:0007592 (facial papules)
Hamartomatous GI polyps (large bowel)	Clinical/ pathologic	85% of CS patients	Adult	HP:0004390
Esophageal glycogenic acanthosis	Pathologic sign	37%	Adult	HP:0100633 (esophageal lesion)
Gastric hamartomatous polyps	Pathologic	47%	Adult	HP:0004394
Duodenal hamartomatous polyps	Pathologic	20%	Adult	—
Thyroid disease (goiter/adenoma/ carcinoma)	Clinical	Common	Adult	HP:0100031
Breast lesions/ carcinoma	Clinical	Lifetime ~85% (women)	Adult	HP:0003002
Lhermitte-Duclos disease (cerebellar)	Clinical/ imaging	Rare but pathognomonic	Adult (usually)	HP:0007266 (dysplastic cerebellar gangliocytoma)

Neurodevelopmental phenotype. A systematic review/meta-analysis "estimated pooled prevalence of ASD characteristics at 25% (95% CI 16-33%)" among individuals with constitutional PTEN mutations PMID: 34983360. In a pediatric PHTS cohort, "macrocephaly was present in 100%, 58% had developmental delays during early childhood, and 17% had an ASD diagnosis" PMID: 37090027. Macrocephaly is thus a near-universal, early, and highly sensitive sign that should prompt genetic evaluation.

Age of onset / severity / progression. Mucocutaneous and neoplastic manifestations are predominantly adult-onset, while macrocephaly and neurodevelopmental features present in childhood. Severity is highly variable even within families (variable expressivity). Cancer risk is progressive and cumulative with age.

Quality-of-life impact. Direct EQ-5D/SF-36 data specific to CS were not identified in this investigation. Qualitatively, QoL is affected by intensive lifelong surveillance burden, repeated surgeries, cancer diagnoses, GI symptoms, and neurodevelopmental/behavioral challenges. The ERN GENTURIS guideline explicitly notes the surveillance program requires significant patient commitment PMID: 42463809.

---

4. Genetic / Molecular Information

Causal gene. PTEN (phosphatase and tensin homolog), HGNC:9588, 10q23.31, OMIM *601728. PTEN encodes a 403-amino-acid dual-specificity phosphatase with an N-terminal phosphatase domain and a C2 (tensin-type) membrane-binding domain.

Pathogenic variants. - **Genes affected:** PTEN (primary); KLLN, SDHB, SDHD (subsets). - **Classification:** pathogenic / likely pathogenic per ACMG/AMP; VUS common for novel missense variants — a pediatric series identified four novel PTEN alterations, with 72% located in the tensin-type C2 domain PMID: 38407606. - **Variant types:** missense, nonsense, frameshift, splice-site, promoter, and structural (10q23 microdeletion encompassing PTEN and BMPR1A) PMID: 20815035. - **Allele frequency:** germline pathogenic PTEN variants are private/rare and effectively absent from population databases (gnomAD) as benign polymorphisms. - **Somatic vs germline:** Cowden syndrome is defined by **germline** variants; somatic second hits occur within lesions. Colorectal juvenile polyps in CS arise from epithelial-specific PTEN loss without a stromal PTEN requirement, per a transgenic mouse model PMID: 24200851. - **Functional consequence:** loss of function / haploinsufficiency (with possible dominant-negative effects for some missense mutants); catalytically inactive stable mutants produce the most severe phenotypes PMID: 25916396.

Epigenetic mechanism (KLLN epimutation). In PTEN wild-type Cowden cases, germline hypermethylation of **KLLN** (which shares a bidirectional promoter with PTEN) has been implicated: "Germline hypermethylation of KLLN, a gene uncovered well after the human genome project, has been linked to Cowden cancer-predisposition syndrome (CS) in PTEN wild-type cases" PMID: 26673699. KLLN maintains pericentric H3K9 trimethylation and genomic stability; its loss causes chromosomal instability, increased micronuclei, and numerical aberrations.

Succinate dehydrogenase (SDHx) variants. In 375 PTEN-mutation-negative CS/CS-like individuals, a subset with mitochondrial dysfunction carried SDH variants: "Among these, 10 (13.5%) had germline mutations/variants in SDHB (n = 3) or SDHD (7), not found in 700 controls ($p < 0.001$)" PMID: 18678321. SDH-variant carriers were enriched for breast, thyroid, and kidney carcinomas.

Biochemical marker — succinate. Both PTEN and SDHx mutation carriers share elevated plasma succinate: "Elevated plasma succinate was observed in 13/21 (62%) individuals with germline PTEN, SDHB, or SDHD mutations as compared with 5/32 (16%) controls ($P < 0.001$)" PMID: 22261759. This suggests a convergent reduction in succinate dehydrogenase activity across genotypes.

Modifier genes. Candidate: SMAD7 PMID: 25554686. **Chromosomal abnormalities:** 10q23 contiguous-gene microdeletions (PTEN + BMPR1A) cause infantile juvenile polyposis with overlapping features PMID: 20815035.

---

5. Environmental Information

Cowden syndrome is a monogenic germline disorder with **no established environmental cause**. There are no confirmed toxic, radiation, pollution, occupational, lifestyle, or infectious triggers. Environmental exposures relevant to sporadic cancers (e.g., radiation, carcinogens) may plausibly modulate cancer expression in carriers, but disease-specific evidence is lacking. **Infectious agents:** not applicable.

---

6. Mechanism / Pathophysiology

Core molecular pathway. PTEN is "a major negative regulator of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (mTOR) signaling pathway-controlling growth, protein synthesis, and proliferation" PMID: 25916396. PTEN dephosphorylates PIP3 → PIP2 at the plasma membrane, opposing PI3K. Loss of PTEN function elevates PIP3, activating AKT and downstream mTORC1, thereby increasing cell growth, protein synthesis, proliferation, and survival while suppressing apoptosis.

Causal chain (ASCII):

```
Germline PTEN LOF (haploinsufficiency)
        │  + somatic 2nd hit in lesion
        ▼
   ↑ PIP3 at plasma membrane
        ▼
   ↑ PI3K → AKT activation
        ▼
   ↑ mTORC1 signaling
        ▼
 ↑ growth / protein synthesis / proliferation, ↓ apoptosis
        ▼
 Hamartomas (skin, GI, cerebellum), overgrowth (macrocephaly),
 neuronal hypertrophy → ASD/DD, and multi-organ carcinogenesis
```

Alternative/convergent axis (PTEN-negative):

```
KLLN promoter hypermethylation → ↓KLLN → loss of H3K9me3 → chromosomal instability
SDHB/SDHD variants → ↓SDH activity → ↑succinate (pseudohypoxia / oncometabolite)
        └──────────────────► shared elevated-plasma-succinate signature ◄──────────────────┘
```

Cellular processes. Dysregulated cell growth/proliferation, reduced apoptosis, and — in the neuronal compartment — enlarged soma, dendritic hypertrophy, increased synaptic density, and altered LTP/LTD contribute to the neurodevelopmental phenotype PMID: 39812527. In PTEN-negative cases, chromosomal instability and increased micronuclei are mechanistic features of KLLN loss PMID: 26673699.

Protein dysfunction. PTEN's phosphatase activity and membrane access are conformationally regulated (open/closed forms; "eased" vs "strained" states affecting the catalytic site and C2 membrane-binding loops) PMID: 40614725. Pathogenic missense variants may impair catalysis, destabilize the protein, or hinder membrane localization.

Metabolic changes. Elevated plasma succinate across PTEN and SDHx carriers points to a shared metabolic disturbance in the TCA cycle/succinate dehydrogenase axis PMID: 22261759.

Tissue/pathway crosstalk. Epithelial PTEN loss drives colorectal juvenile polyp formation via altered epithelial–mesenchymal crosstalk, without requiring stromal PTEN loss PMID: 24200851. STAT5–PI3K/AKT cooperativity accelerates mammary tumorigenesis in a Cowden mouse model, and mammary-specific Stat5 ablation prevents carcinogenesis in PTEN-mutant mice PMID: 24469394.

Suggested ontology terms. GO:0046855 (phosphatidylinositol dephosphorylation); GO:0014065 (PI3K signaling); GO:0031929 (TOR signaling); GO:0008285 (negative regulation of cell proliferation); GO:0006915 (apoptotic process). CL terms: CL:0000066 (epithelial cell), CL:0000540 (neuron), CL:0002251 (epithelial cell of alimentary canal).

---

7. Anatomical Structures Affected

Organ level (primary): breast (UBERON:0000310), thyroid gland (UBERON:0002046), endometrium/uterus (UBERON:0001295 / UBERON:0000995), kidney (UBERON:0002113), colon/large intestine (UBERON:0001155), skin (UBERON:0002097), cerebellum (UBERON:0002037), gastrointestinal tract broadly (esophagus, stomach, duodenum).

Body systems involved: integumentary, endocrine, digestive, genitourinary/reproductive, nervous, and (rarely) respiratory (bronchial carcinoids reported) PMID: 38353885.

Tissue/cell level: predominantly epithelial tissue (breast ductal, thyroid follicular, colonic/gastric epithelium, trichilemmal skin epithelium) plus mesenchymal/stromal components in GI hamartomas (lymphoid, lipomatous, ganglioneuromatous elements were common in the 43-patient cohort) PMID: 31273317. Cerebellar involvement features dysplastic ganglion/granule neurons (Lhermitte-Duclos).

Suggested CL terms: CL:0002327 (mammary gland epithelial cell), CL:0002258 (thyroid follicular cell), CL:0011108 (colonic epithelial cell), CL:0000121 (Purkinje cell), CL:0000540 (neuron).

Subcellular level: plasma membrane (GO:0005886) where PTEN acts on PIP3; nucleus (PTEN nuclear functions in genomic stability); mitochondria (GO:0005739) implicated via SDHx/succinate metabolism.

Localization / lateralization: lesions are typically multifocal and bilateral (e.g., bilateral breast disease, bilateral GI polyposis). Lhermitte-Duclos lesions are often unilateral cerebellar but can be diffuse PMID: 27932596.

---

8. Temporal Development

Onset. Macrocephaly is congenital/early; neurodevelopmental features emerge in childhood; mucocutaneous lesions and neoplasia are predominantly adult-onset. Overall course is **chronic and lifelong** with an **insidious** onset.

Progression. Benign hamartomas are typically slow-growing/stable, but carry premalignant potential in some tissues; cancer risk is progressive and age-cumulative. Colorectal juvenile polyps can undergo dysplastic transformation to carcinoma PMID: 24200851. Lhermitte-Duclos disease is slow-growing but can cause obstructive hydrocephalus and brainstem compression requiring intervention PMID: 27932596.

Patterns / critical periods. No spontaneous remission of the underlying genetic disorder occurs. Critical intervention windows include childhood (early diagnosis via macrocephaly to enable surveillance) and the adult decades of peak cancer incidence, when surveillance and risk-reducing surgery are most impactful.

---

9. Inheritance and Population

Inheritance. Autosomal dominant. Penetrance is high but **incomplete and age-dependent**; **expressivity is highly variable** even within families PMID: 26827793. A significant proportion of cases are de novo. Germline mosaicism and founder effects are not prominent features. Consanguinity is not a driver (dominant disorder).

Epidemiology. Cowden syndrome is rare; commonly cited prevalence estimates are on the order of ~1 in 200,000–250,000, though this is likely an underestimate given variable expressivity and underdiagnosis. Precise incidence figures were not established in this investigation.

Population demographics. No strong ethnic predilection is established. Sex influences expression: female carriers bear high breast and endometrial cancer risk. Pediatric presentation is dominated by macrocephaly and neurodevelopmental features; adult presentation by mucocutaneous lesions and neoplasia.

Genotype–geography of variants: PTEN variants are private; no dominant founder variant identified.

---

10. Diagnostics

Clinical diagnostic criteria. Diagnosis uses established **PTEN hamartoma tumor syndrome / Cowden syndrome clinical criteria (2013 revision)** combining pathognomonic, major, and minor criteria; the **Cleveland Clinic PTEN risk calculator** estimates the probability of a PTEN mutation to guide testing (e.g., an 82–98% predicted probability triggered testing in one case) PMID: 37680909; PMID: 39044874.

Genetic testing (recommended, definitive). Germline **PTEN** sequencing plus deletion/duplication analysis is the primary test. Multi-gene hereditary cancer/polyposis panels and, in PTEN-negative cases, evaluation for KLLN methylation and SDHB/SDHD variants are appropriate. Chromosomal microarray detects 10q23 microdeletions. In pediatrics, targeted/stepwise testing is advised because of autonomy and psychosocial considerations PMID: 42353760. Significant macrocephaly in a child should prompt a genetic study for early diagnosis PMID: 38407606.

Imaging. Thyroid ultrasound; breast MRI/mammography; endometrial and renal imaging; brain MRI shows the pathognomonic cerebellar "tiger-stripe" pattern of Lhermitte-Duclos disease on T2-weighted images PMID: 40763010. Brain 18F-FDG PET can complement MRI to characterize neuropsychiatric/movement features PMID: 35006113.

Endoscopy / pathology. Upper and lower GI endoscopy reveals characteristic lesions; histopathology of hamartomatous polyps with mixed stromal (lymphoid, lipomatous, ganglioneuromatous) elements and esophageal glycogenic acanthosis is diagnostically suggestive PMID: 31273317; PMID: 28901964.

Candidate biomarker. Elevated plasma succinate distinguishes PTEN/SDHx carriers from controls and may serve as an adjunct biochemical marker PMID: 22261759.

Differential diagnosis. Other PHTS entities (BRRS, Proteus), juvenile polyposis syndrome (SMAD4/BMPR1A), Peutz-Jeghers syndrome (STK11), other macrocephaly-ASD monogenic conditions, and sporadic hamartomatous polyps PMID: 28901964; PMID: 40282429.

Screening. Cascade genetic testing of at-risk relatives is standard once a familial variant is identified.

---

11. Outcome / Prognosis

Cancer-driven prognosis. The prognosis is dominated by lifetime cancer risk. The landmark prospective study reported: "Elevated SIRs were found for carcinomas of the breast [25.4, 95% confidence interval (CI), 19.8-32.0], thyroid (51.1, 38.1-67.1), endometrium (42.9, 28.1-62.8), colorectum (10.3, 5.6-17.4), kidney (30.6, 17.8-49.4), and melanoma (8.5, 4.1-15.6)" PMID: 22252256.

Cancer	SIR	Estimated lifetime risk
Breast	25.4	~85.2%
Thyroid	51.1	~35.2%
Endometrial	42.9	~28.2%
Kidney	30.6	~33.6%
Colorectal	10.3	~9.0%
Melanoma	8.5	~6.0%

Morbidity/function. Neurodevelopmental features (ASD ~25%, developmental delay ~58% in pediatric cohorts) and repeated surgical/surveillance interventions contribute to disability and QoL impact PMID: 34983360; PMID: 37090027. Lhermitte-Duclos disease can cause life-threatening hydrocephalus/brainstem compression PMID: 27932596.

Prognostic factors. Genotype (promoter mutation → breast cancer; nonsense → colorectal cancer), sex, age, and adherence to surveillance influence outcomes PMID: 22252256. With early diagnosis and guideline surveillance, many cancers are detected early and are treatable, substantially improving outcomes.

---

12. Treatment

Overall strategy. There is no cure; management centers on **surveillance, early cancer detection, and risk-reducing surgery**, per ERN GENTURIS and NCCN guidelines PMID: 42463809.

Surgical/interventional. Cancer-directed surgery (e.g., thyroidectomy, mastectomy, hysterectomy), consideration of risk-reducing mastectomy/hysterectomy in high-risk carriers, polypectomy, and neurosurgical resection/decompression for symptomatic Lhermitte-Duclos disease PMID: 40469941; PMID: 36131570.

Targeted therapy — mTOR inhibition (experimental). Because PTEN loss de-represses mTOR, mTOR inhibitors are mechanistically rational (NCIT: everolimus, sirolimus/rapamycin). - **Anecdotal success:** In infantile Lhermitte-Duclos disease where surgery was not feasible, rapamycin produced dramatic improvement: "Within 5 months, our patient has become responsive to her surroundings and had return of spontaneous breathing. Repeat magnetic resonance imaging (MRI) reveals lack of brainstem compression or distortion of pituitary stalk. Rapamycin should be considered in cases of Lhermitte-Duclos disease where surgical removal may not be an option" PMID: 27932596. - **RCT — negative primary endpoint:** In a phase II randomized double-blind placebo-controlled trial of everolimus for neurocognitive symptoms in PHTS (n=46), "Changes in the primary endpoint between groups from baseline to Month 6 were not apparent (Cohen's d = -0.10, P = 0.518). However, several measures were associated with modest effect sizes (≥0.2) in the direction of improvement, including measures of nonverbal IQ, verbal learning, autism symptoms, motor skills, adaptive behavior and global improvement" PMID: 35594551. GI adverse events were more common with everolimus (P<0.001).

Pharmacogenomics / personalized medicine. Genotype-guided surveillance intensity is emerging (promoter vs nonsense correlations); no validated CS-specific pharmacogenomic dosing exists.

Supportive/rehabilitative. Neurodevelopmental support (behavioral, speech, occupational therapy) for affected children; symptom management for GI disease.

Suggested NCIT terms: Everolimus (C48387), Sirolimus/Rapamycin (C1212), Mastectomy (C15277), Thyroidectomy (C15400), Genetic Counseling (C15315).

13. Prevention

Primary prevention. Not applicable at the level of preventing the germline disorder; genetic counseling and reproductive options (preimplantation/prenatal diagnosis) can prevent transmission.

Secondary prevention (core of management). Intensive organ-specific cancer surveillance for early detection. The ERN GENTURIS guideline states: "PTEN hamartoma tumour syndrome (PHTS) is a diverse multi-system disorder predisposing to a high hereditary risk of breast, thyroid, endometrial, and a moderate risk of renal, and colorectal cancer and skin melanoma" and recommends coordinated multidisciplinary surveillance covering these organs PMID: 42463809. Typical elements: annual thyroid ultrasound, breast MRI/mammography, endometrial and renal surveillance, dermatologic exam, and colonoscopy.

Tertiary prevention. Risk-reducing surgery in high-risk carriers; treatment of premalignant polyps; management of Lhermitte-Duclos complications.

Counseling. Genetic counseling and cascade testing of relatives are essential; the guideline emphasizes the substantial patient commitment required and the need for prospective evaluation of surveillance effectiveness PMID: 42463809.

Immunization / public health / infectious prophylaxis: not applicable.

---

14. Other Species / Natural Disease

Taxonomy / orthologs. PTEN is highly conserved. Human PTEN (NCBI Gene 5728) has a mouse ortholog *Pten* (NCBI Gene 19211, on mouse chromosome 19). PTEN "encodes a protein... Located on chromosome 10 in humans and chromosome 19 in mice" PMID: 39812527.

Natural disease in animals. Cowden syndrome as a defined germline hereditary syndrome is a human condition; no equivalent naturally occurring hereditary syndrome is established in companion animals. However, PTEN loss/reduced expression is documented in **canine gliomas**, paralleling human tumor biology: reduced PTEN immunopositivity occurred in a substantial fraction of canine gliomas, "in line with those reported in human gliomas" PMID: 39061577 — relevant to comparative oncology rather than to inherited CS.

Comparative biology. The deep evolutionary conservation of PTEN and the PI3K/AKT/mTOR axis underlies the utility of model organisms. **Zoonotic potential:** not applicable.

15. Model Organisms

Mouse models (principal). - **Epithelial-specific Pten deletion** recapitulates colorectal juvenile polyposis: "we find epithelial-specific PTEN deletion to cause formation of juvenile polyps in the colorectum... these lesions closely recapitulate all of the characteristic histopathological features of juvenile polyps seen in patients with CS, including stromal alterations and dysplastic transformation to colorectal carcinoma" PMID: 24200851. This model demonstrated stromal PTEN loss is not a prerequisite and validated altered epithelial–mesenchymal crosstalk. - **Mammary Cowden model:** constitutive Stat5 activation cooperates with Pten loss to accelerate mammary tumors, and "mammary gland-specific ablation of Stat5 is sufficient to prevent mammary carcinogenesis in a genuine mouse model for Cowden syndrome" PMID: 24469394. - **Neuronal Pten models** reproduce enlarged soma, dendritic hypertrophy, increased synaptic density, altered LTP/LTD, and deficits in learning/memory and social behavior — recapitulating the macrocephaly/ASD phenotype PMID: 39812527.

Model types available: conditional (tissue-specific Cre) knockouts, transgenic, and germline heterozygous *Pten*+/− mice. **Applications:** studying carcinogenesis, hamartoma formation, neurodevelopmental mechanisms, and mTOR-inhibitor efficacy. **Limitations:** single-tissue conditional models capture individual manifestations but not the full multi-system syndrome; species differences in cancer spectrum and lifespan limit direct translation.

Resources: MGI (Pten), IMPC/IMSR for mouse alleles.

Mechanistic Model / Interpretation

Cowden syndrome is best understood as a **PTEN-dosage disease with a convergent metabolic/genomic-instability tail**. The dominant axis is germline PTEN haploinsufficiency plus somatic second hits, releasing the PI3K/AKT/mTOR brake to drive hamartomatous overgrowth, neuronal hypertrophy (macrocephaly, ASD), and multi-organ carcinogenesis. Genotype tunes phenotype: catalytically dead-but-stable mutants → severe; partial-function → milder/ASD-predominant; promoter mutations → breast; nonsense → colorectal.

A parallel, smaller stream explains PTEN-negative "Cowden-like" cases: **KLLN epimutation** (genomic instability via loss of pericentric H3K9me3) and **SDHx variants** (mitochondrial dysfunction). Remarkably, both PTEN and SDHx carriers share an **elevated-succinate** signature, hinting at a metabolic node connecting otherwise distinct genotypes — a potential unifying biomarker and therapeutic hypothesis.



Evidence Base

PMID	Contribution	Role
22252256	Prospective SIRs and lifetime cancer risks (breast, thyroid, endometrial, renal, colorectal, melanoma)	Supports cancer-risk profile (F001)
26827793	PTEN germline LOF as cause; phenotype prediction	Supports etiology (F002)
25916396	PTEN as PI3K/AKT/mTOR regulator; genotype–severity	Mechanism (F002)
34983360	ASD prevalence 25% meta-analysis	Neuro phenotype (F003)
37090027	Macrocephaly 100%, DD 58% pediatric	Neuro phenotype (F003)
31273317	GI polyposis spectrum, 43-patient cohort	GI phenotype (F004)
42463809	ERN GENTURIS surveillance guideline	Prevention/ management (F005)
27932596	Rapamycin response in Lhermitte-Duclos	Targeted therapy (F006)
35594551	Everolimus RCT (negative primary endpoint)	Targeted therapy (F007)
26673699	KLLN epimutation & genomic instability	Heterogeneity (F008)
18678321	SDHB/SDHD variants in PTEN-negative CS	Heterogeneity (F008)
22261759	Elevated plasma succinate biomarker	Biomarker (F009)
24200851	Epithelial Pten-KO colorectal polyp mouse model	Model organism
24469394	Stat5/PI3K Cowden mammary mouse model	Model organism
39812527	PTEN in CNS; neuronal phenotypes; mouse ortholog	Mechanism/model
40614725	PTEN conformational regulation	Protein dysfunction
25554686	PTEN frameshift + SMAD7 modifier; esophageal cancer	Modifier/etiology
39061577	PTEN loss in canine gliomas	Comparative biology

Limitations and Knowledge Gaps

1. **QoL data:** No CS-specific EQ-5D/SF-36/PROMIS metrics were identified; QoL impact is described qualitatively.
2. **Epidemiology precision:** Prevalence/incidence figures are approximate and likely underestimated; no primary registry-derived incidence was verified in this investigation.
3. **Surveillance effectiveness:** The ERN GENTURIS guideline itself notes the need for prospective evaluation of whether intensive surveillance improves survival PMID: 42463809.
4. **Targeted therapy uncertainty:** mTOR-inhibitor benefit rests on anecdotes for hamartomas plus a **negative** primary RCT endpoint for neurocognition; efficacy for cancer prevention is unproven.
5. **PTEN-negative subsets:** KLLN and SDHx contributions come from single-center studies requiring independent replication; the mechanistic link between succinate elevation and PTEN loss remains hypothesis-level.
6. **Genotype–phenotype:** Correlations (promoter→breast, nonsense→colorectal) are associations that need validation in independent cohorts.

Proposed Follow-up Experiments / Actions

1. **Prospective surveillance outcome study** — quantify whether guideline surveillance reduces cancer mortality in PHTS, addressing the explicit ERN GENTURIS gap.
2. **Succinate biomarker validation** — replicate elevated plasma succinate as a diagnostic/monitoring biomarker across PTEN, KLLN, and SDHx subgroups in a larger, controlled cohort.
3. **Mechanistic dissection of the PTEN–succinate link** — test whether PTEN loss lowers SDH catalytic activity, potentially unifying the PTEN and SDHx metabolic phenotypes.
4. **Genotype-stratified surveillance trial** — prospectively test intensified organ-specific screening guided by variant class (promoter/nonsense/missense).
5. **Targeted-therapy trials with tumor endpoints** — evaluate mTOR/PI3K inhibitors for hamartoma burden and cancer prevention (not just neurocognition), with biomarker-based patient selection.

6. **Registry-based epidemiology** — derive robust prevalence, incidence, penetrance, and de novo rates from multinational PHTS registries.

Report compiled from 9 confirmed findings and 38 reviewed papers over 5 investigation iterations. Evidence types span human clinical cohorts, guideline consensus, model-organism studies, in vitro/structural work, and comparative pathology.
